poisar

Stock

Radiopharm Theranostics Limited RADX

$3.09-6.65%

Overview

RADX market data

Price History

RADX price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.02
Diluted earnings per share over the trailing twelve months.
Beta
1.19
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$0.01 – $0.04
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $49.6 · P/B 1.16 · P/S 13.65.

Company News

9 captured
12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · Jul 24, 2026, 5:05 PM
US Stocks Mixed; American Express Shares Fall Following Q2 ResultsBenzinga · Jul 24, 2026, 1:45 PM
Radiopharm Theranostics Announces $4.1M U.S. Direct Offering Of Shares And Warrants Along With A$12.7M ($8.9M) Australian PlacementBenzinga · Jul 24, 2026, 11:18 AM
Trading Halt: Halt status updated at 7:00:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga · Jul 24, 2026, 11:00 AM
Radiopharm Theranostics Announces Updated Clinical Results From First Two Patients In Third Cohort Of RAD204; First RECIST-Confirmed Durable Partial Response At Current Highest Dose Level #3, With Patient Progression Free Beyond Seven MonthsBenzinga · Jul 22, 2026, 11:10 AM
Radiopharm Theranostics Announces Data From All Thirty Evaluable Patients In Its Phase 2B Trial Of RAD101 In Participants With Suspected Recurrence Of Brain Metastases After Radiotherapy; RAD101 PET Demonstrated 93% Concordance With MRI Across All Evaluable Lesions, Meeting The Primary EndpointBenzinga · Jul 22, 2026, 11:08 AM
Trading Halt: Halted at 7:56:55 p.m. ET - Trading Halt: Halt News PendingBenzinga · Jul 21, 2026, 11:56 PM
This HC Wainwright & Co. Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For ThursdayBenzinga · Jun 4, 2026, 1:40 PM
HC Wainwright & Co. Initiates Coverage On Radiopharm Theranostics with Buy Rating, Announces Price Target of $16Benzinga · Jun 4, 2026, 11:20 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock